EC Number   |
Activating Compound |
Reference |
|---|
   3.4.24.B12 | interleukin-1alpha |
increase of ADAMTS-5 in wild-type mice |
695954 |
| 3.4.24.B12 | interleukin-1alpha |
increased transcription in the presence of interleukin-1alpha |
679600 |
| 3.4.24.B12 | interleukin-1beta |
increased transcription in the presence of interleukin-1beta |
679600 |
| 3.4.24.B12 | more |
ADAMTS5 expression is not stimulated by interleukin-1, tumor necrosis factor alpha, oncostatin M or transforming growth factor beta |
679302 |
| 3.4.24.B12 | more |
higher enzyme expression in degenerated intervertebral discs |
695958 |
| 3.4.24.B12 | more |
higher expression level in metastatic foci compared with corresponding primary tumor |
698148 |
| 3.4.24.B12 | more |
little effect from interleukin-1alpha and retinoate on aggrecanase activity |
680863 |
| 3.4.24.B12 | more |
syndecan-4 controls the activation of ADAMTS-5 through direct interaction with the protease and through regulating mitogen-activated protein kinase (MAPK)-dependent synthesis of matrix metalloproteinase-3 (MMP-3). Syndecan-4 is crucial in regulating Mmp-3 expression by activating ERK1/2 and by targeting ADAMTS-5 to the cell surface of chondrocytes |
710041 |
| 3.4.24.B12 | NaCl |
optimal aggrecanase activity for ADAMTS-5 is detected around 200 mM NaCl |
680781 |
| 3.4.24.B12 | NaCl |
optimum concentration for aggrecan degradation is 200 mM |
720093 |
